Bliss Biopharmaceutical (Hangzhou) Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private, Subsidiary, Holding
- Established
- 2017-12-07
- Employees
- -
- Market Cap
- -
A First-in-human of Multiplle Doses of BB-1709 in Subjects With Locally Advanced/Metastatic Solid Tumors
- First Posted Date
- 2024-02-05
- Last Posted Date
- 2024-02-05
- Lead Sponsor
- Bliss Biopharmaceutical (Hangzhou) Co., Ltd
- Target Recruit Count
- 300
- Registration Number
- NCT06241898
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
A First-in-human of Multiplle Doses of BB-1705 in Subjects With Locally Advanced/Metastatic Solid Tumors
- First Posted Date
- 2022-02-01
- Last Posted Date
- 2023-12-20
- Lead Sponsor
- Bliss Biopharmaceutical (Hangzhou) Co., Ltd
- Target Recruit Count
- 288
- Registration Number
- NCT05217693
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, China
🇨🇳Hunan Cancer Hospital, Changsha, China
🇨🇳First affiliated hospital of Gannan medical university, Ganzhou, China
A First-in-human Study of Multiple Doses of BB-1701 in Subjects With Locally Advanced/Metastatic HER2 Expressing Solid Tumors
Phase 1
Active, not recruiting
- Conditions
- Locally Advanced/Metastatic HER2 Positive Solid Tumors
- Interventions
- First Posted Date
- 2020-02-05
- Last Posted Date
- 2023-12-15
- Lead Sponsor
- Bliss Biopharmaceutical (Hangzhou) Co., Ltd
- Target Recruit Count
- 208
- Registration Number
- NCT04257110
- Locations
- 🇺🇸
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
🇺🇸Sarah Cannon Research, Nashville, Tennessee, United States
🇺🇸The Regents of NEXT Virginia, LLC, Fairfax, Virginia, United States